ANNIE ANDREWS: Open Payments
NPI 1902301500 · PELHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,059 in 91 payments from 18 companies in 2025. Trend: 2023 $617 · 2024 $1,796 · 2025 $2,059
Food & beverage: $2,059
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 14 | $364 |
| Vanda Pharmaceuticals Inc. | 11 | $330 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $300 |
| Teva Pharmaceuticals USA, Inc. | 9 | $164 |
| Axsome Therapeutics, Inc. | 7 | $126 |
| Corium, LLC | 6 | $119 |
| Alkermes, Inc. | 4 | $90 |
| Tris Pharma Inc | 4 | $85 |
| Lundbeck LLC | 3 | $84 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $78 |
Products named: INGREZZA, FANAPT, CAPLYTA, UZEDY, Auvelity, Azstarys, REXULTI, ARISTADA.
Industry payments across AL — which companies pay providers there.
